JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.14 -20.28

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1

Max

1.43

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+179.86% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	76M 571M
Eelmine avamishind	21.42
Eelmine sulgemishind	1.14

Uudiste sentiment

By Acuity

100%

334 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. jaan 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30. jaan 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30. jaan 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30. jaan 2026, 22:20 UTC

Tulu

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30. jaan 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. jaan 2026, 21:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 21:36 UTC

Tulu

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30. jaan 2026, 21:33 UTC

Tulu

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30. jaan 2026, 20:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30. jaan 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30. jaan 2026, 19:52 UTC

Tulu

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30. jaan 2026, 19:29 UTC

Market Talk

Tulu

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30. jaan 2026, 19:07 UTC

Market Talk

Canada Performing Well Below Economic Potential -- Market Talk

30. jaan 2026, 18:46 UTC

Tulu

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30. jaan 2026, 18:34 UTC

Tulu

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

179.86% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 179.86%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

334 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.